Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BeOne Medicines Ltd. - Sponsored ADR (ONC) vs Roivant Sciences Ltd. (ROIV)

BeOne Medicines Ltd. - Sponsored ADR and Roivant Sciences Ltd. are both Biotechnology companies. BeOne Medicines Ltd. - Sponsored ADR is the larger, with a market value of $37.3B against $25.6B — 1.5× the size. Roivant Sciences Ltd. has negative trailing earnings, so its P/E is not meaningful; BeOne Medicines Ltd. - Sponsored ADR trades at 61.2×. BeOne Medicines Ltd. - Sponsored ADR grew revenue faster over the last twelve months: 34.4% against −67.6%. BeOne Medicines Ltd. - Sponsored ADR has the higher net margin (10.7% vs −3,535.0%) and the higher return on invested capital (60.2% vs −34.5%). Across the 18 metrics below, BeOne Medicines Ltd. - Sponsored ADR leads on 15 and Roivant Sciences Ltd. on 3.

Valuation

Metric ONC ROIV Biotechnology median
P/E 61.16 n/m 7.88
P/S 6.57 3,425.89 11.47
P/B 7.78 5.24 2.52
Price to free cash flow 30.73 n/m 21.16
EV/EBITDA 34.08 n/m 0.74
EV/Sales 5.99 2,958.77 10.73
Earnings yield 1.64% (1.06%) (28.84%)
Free cash flow yield 3.25% (3.18%) (23.03%)

Profitability

Metric ONC ROIV Biotechnology median
Gross margin 88.89% 81.21% 65.16%
Operating margin 15.06% (7,914.75%) 0.00%
Net margin 10.70% (3,534.96%) 0.00%
Free cash flow margin 21.70% (10,901.00%) 0.00%
Return on equity 14.66% (5.47%) (57.72%)
Return on assets 8.47% (5.15%) (49.22%)
Return on invested capital 60.22% (34.51%) 0.00%

Growth

Metric ONC ROIV Biotechnology median
Revenue growth (TTM) 34.35% (67.58%) 5.64%
EPS growth (last fiscal year) 141.34% (125.00%) —
Revenue growth, 5-year CAGR 76.85% (19.07%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ONC ROIV Biotechnology median
Debt to equity 0.17 0.00 0.00
Current ratio 3.41 16.72 4.73
Net debt to EBITDA (6.09) 8.39 0.96

Dividend

Metric ONC ROIV Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ONC ROIV Biotechnology median
Market cap 37.25b 25.64b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack